Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

rage percent improvement in contracture from baseline was 8.6% (49.1 degrees average contracture at baseline down to 45.7 degrees average contracture after placebo treatment) (p<0.001). Second, 84.7% of patients (172 of 203) treated with XIAFLEX achieved at least a 50% reduction in their primary joint contracture from baseline, compared with 11.7% of patients (12 of 103) treated with placebo (p<0.001).

Dr. Lawrence Hurst, M.D., Professor and Chair, Department of Hand Surgery, Department of Orthopaedics of the Health Science Center, State University of New York at Stony Brook, an investigator in the CORD I clinical trial, said, "I believe these clinical results are very encouraging for patients with Dupuytren's contracture. As a surgeon, I am pleased to get contracture improvement to < / = 5 degrees of normal in 50-60% of patients who undergo surgery. Based on the risk/benefit profile demonstrated in the data released today, I would anticipate that XIAFLEX will offer a strong therapeutic alternative to surgery and could potentially become the new first-line treatment option for Dupuytren's contracture."

CORD II Efficacy Results

CORD II enrolled a total of 66 Dupuytren's contracture patients in five clinical sites across Australia. Forty-five patients received XIAFLEX and 21 received placebo in the double-blind portion of the study. The joints were stratified 1:1 MP to PIP. The primary endpoint was met, with 44.4% (20 of 45) of patients' primary joints treated with XIAFLEX achieving

Within the CORD II study, average percent improvement in contracture from baseline was 70.5% (53.2 degrees average contracture at baseline down to 16.7 degrees average contracture after treatment) for primary joints treated w
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... -- Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... the fourth quarter and year ended December 31, 2014. ... less than $0.01 per share, on revenues of $8,018,000 ... with net income of $195,000, or $0.01 per share, ... 2013. The substantial increase in fourth quarter 2014 revenue ...
(Date:3/6/2015)... , March 6, 2015  AbbVie (NYSE: ... Health Care Conference on Thursday, March 12, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... 5, 2012 Cogmedix , ... device companies cost effectively improve their time-to-market, partnered ... the company,s refractive cataract surgery laser system. Designed ... critical manual steps in cataract surgery, the LensAR ...
... Officer of the American Telemedicine Association, has shared ... telehealth in the immediate future.  These trends represent ... challenges and opportunities for the industry.  ... 1. A Shift away from reimbursement models ...
Cached Medicine Technology:Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 3
(Date:3/6/2015)... 06, 2015 “On Tap” takes the audience ... grand stage, to the silver screen and to modern day ... toe-tapping numbers and their famous eye-high kicks! Producers, directors and ... history of tap dancing in this robust show, showcasing one ... the United States. , “On Tap” is proud to ...
(Date:3/6/2015)... San Rafael, CA (PRWEB) March 06, 2015 ... the addition of three Maryland camps – two non-contact ... camps will be run by Perfect Performance Training, located ... camps will focus on developing position specific skills, speed ... will be hosted at Salisbury University with Marvin Graves, ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit with ... in Superior Court in the State of California in ... 12 awarded Mrs. Perry $700,000 in actual damages for ... TVT Abbrevo plastic sling for stress urinary incontinence. The ... $5 million in punitive damages. , According to court ...
(Date:3/6/2015)... First Choice Emergency Room opened ... is located at 13351 W. Bowles Avenue, Littleton, Colorado and ... ready 24-7 to provide the highest quality emergency medical care ... of First Choice Emergency Room Littleton. , First ... Metro Denver Chamber of Commerce and a medical community open ...
Breaking Medicine News(10 mins):Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
... inclination, study finds , WEDNESDAY, June 17 (HealthDay News) -- Bad ... violent street gangs. But a new study finds that the urge ... genes. , Boys who have a variant of the gene monoamine ... are not only more likely to be in gangs than boys ...
... , - SLA Centennial Observance ... Century , Elsevier has been awarded ... BioMedicine and the Life Sciences" at the Special Library,Association,s (SLA) ... published by Elsevier, many on behalf of renowned,societies, were also ...
... in Health and Life Sciences Category , , SUNNYVALE, ... Incorporated (Nasdaq: ARAY ), a global leader in ... the company,s president and CEO, received the Ernst & Young ... Life Sciences category in Northern California. According to Ernst ...
... has begun , , PITTSBURGH, June 17 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. ... Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This ... and 30 mg strengths of the product. , , ...
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... agreement with Deerfield Management, a leading healthcare investment organization and ... funding through a credit facility. , , "We ... the potential of our business and that we have the ...
... the development of TMC207 and the discovery of new ... 17 A new landmark collaboration between the Global ... product development partnership, and Tibotec Inc., (Tibotec), a global ... Health Summit in response to the urgent need to ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 2Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy...
Medicine Products: